Free Trial

Totally (TLY) Competitors

Totally logo
GBX 9.25 0.00 (0.00%)
(As of 11/15/2024 ET)

TLY vs. KNB, SPI, MGP, SBI, ORPH, CREO, KOO, SPEC, REDX, and ETX

Should you be buying Totally stock or one of its competitors? The main competitors of Totally include Kanabo Group (KNB), Spire Healthcare Group (SPI), Medica Group (MGP), Sourcebio International (SBI), Open Orphan (ORPH), Creo Medical Group (CREO), Kooth (KOO), INSPECS Group (SPEC), Redx Pharma (REDX), and e-therapeutics (ETX). These companies are all part of the "medical" sector.

Totally vs.

Totally (LON:TLY) and Kanabo Group (LON:KNB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.

Totally presently has a consensus target price of GBX 20, suggesting a potential upside of 116.22%. Given Totally's stronger consensus rating and higher possible upside, equities research analysts plainly believe Totally is more favorable than Kanabo Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Totally
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kanabo Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Totally has higher revenue and earnings than Kanabo Group. Totally is trading at a lower price-to-earnings ratio than Kanabo Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Totally£106.68M0.17-£3.13M-£0.02-462.50
Kanabo Group£1.14M5.55-£8.18M-£0.01-100.00

In the previous week, Totally's average media sentiment score of 0.66 beat Kanabo Group's score of 0.00 indicating that Totally is being referred to more favorably in the media.

Company Overall Sentiment
Totally Positive
Kanabo Group Neutral

51.3% of Totally shares are owned by institutional investors. Comparatively, 3.8% of Kanabo Group shares are owned by institutional investors. 13.3% of Totally shares are owned by company insiders. Comparatively, 37.0% of Kanabo Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Totally received 131 more outperform votes than Kanabo Group when rated by MarketBeat users.

CompanyUnderperformOutperform
TotallyOutperform Votes
131
72.78%
Underperform Votes
49
27.22%
Kanabo GroupN/AN/A

Totally has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Kanabo Group has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500.

Kanabo Group has a net margin of 0.00% compared to Totally's net margin of -2.94%. Totally's return on equity of -8.85% beat Kanabo Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Totally-2.94% -8.85% -2.42%
Kanabo Group N/A -83.19%-20.89%

Summary

Totally beats Kanabo Group on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLY vs. The Competition

MetricTotallyMedical Care Facilities IndustryMedical SectorLON Exchange
Market Cap£18.18M£1.41B£5.15B£1.65B
Dividend Yield13.16%3.79%5.18%6.87%
P/E Ratio-462.50207.7666.671,777.52
Price / Sales0.1761.401,276.84252,130.22
Price / Cash9.0813.4539.7027.60
Price / Book0.542.276.472.84
Net Income-£3.13M£52.03M£119.73M£158.93M
7 Day Performance-5.13%-0.85%-5.13%-0.63%
1 Month Performance19.35%-1.90%-2.71%3.39%
1 Year Performance26.37%12.05%31.08%126.08%

Totally Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLY
Totally
3.5106 of 5 stars
GBX 9.25
flat
GBX 20
+116.2%
+30.3%£18.18M£106.68M-462.501,668
KNB
Kanabo Group
N/AGBX 0.90
-10.0%
N/A-21.6%£5.69M£1.14M-90.0020Gap Down
SPI
Spire Healthcare Group
2.9425 of 5 stars
GBX 216
-0.5%
N/A-2.7%£872.25M£1.44B3,085.71420News Coverage
MGP
Medica Group
N/AGBX 211
flat
N/A+0.0%£259.85M£76.98M3,516.671,212
SBI
Sourcebio International
N/AGBX 115
+4.5%
N/AN/A£85.31M£75.61M1,277.78194Gap Up
High Trading Volume
ORPH
Open Orphan
N/AGBX 10
+5.3%
N/AN/A£67.09M£34.71M-25.30179
CREO
Creo Medical Group
N/AGBX 18.11
-0.8%
N/A-47.3%£65.50M£30.30M-301.75279
KOO
Kooth
N/AGBX 169
flat
N/A-46.0%£61.65M£54.17M1,408.33478
SPEC
INSPECS Group
N/AGBX 59
-4.1%
N/A-32.9%£59.99M£195.14M-19.221,673Gap Down
REDX
Redx Pharma
N/AGBX 15
+31.6%
N/A-42.3%£58.35M£4.20M-150.00101Gap Up
High Trading Volume
ETX
e-therapeutics
N/AGBX 9
-6.7%
N/AN/A£52.59M£295,000.00-450.0035High Trading Volume

Related Companies and Tools


This page (LON:TLY) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners